Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Bought by DDD Partners LLC

DDD Partners LLC increased its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 165.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 601,050 shares of the company's stock after acquiring an additional 374,976 shares during the period. DDD Partners LLC owned approximately 0.09% of Genmab A/S worth $11,769,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Barclays PLC boosted its position in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Genmab A/S during the fourth quarter worth $60,000. Aquatic Capital Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth $114,000. Finally, Blue Trust Inc. boosted its holdings in Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after purchasing an additional 4,666 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

Shares of GMAB traded down $0.13 during midday trading on Friday, reaching $21.88. 837,917 shares of the stock were exchanged, compared to its average volume of 1,254,126. The business's 50-day moving average price is $21.18 and its 200 day moving average price is $20.78. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.56. The company has a market capitalization of $14.04 billion, a price-to-earnings ratio of 12.43, a PEG ratio of 6.69 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. As a group, equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GMAB shares. Truist Financial lifted their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.